B. Goldman

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

T. Wadden, S. Calanna, M. Thomsen, 2021, Diabetes, obesity & metabolism.

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

T. Wadden, M. Davies, R. Kushner, 2020, Obesity.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.

N. Poulter, J. Buse, R. Pratley, 2020, Journal of the American College of Cardiology.

Recombinant long‐acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials

C. Négrier, G. Young, P. Collins, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

P2518Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

N. Poulter, M. Nauck, S. Bain, 2018 .

NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL

N. Poulter, M. Nauck, S. Bain, 2018 .

Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".

N. Poulter, V. Fonseca, I. Raz, 2019, Circulation.

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment

T. Hansen, P. Rossing, F. Persson, 2019, Diabetes, obesity & metabolism.

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

N. Poulter, V. Fonseca, I. Raz, 2018, Circulation.

Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline

B. Goldman, H. K. Nielsen, Stephanie Dechiaro, 2021, Frontiers in Medicine.